JMJD3 facilitates C/EBP尾-centered transcriptional program to exert oncorepressor activity in AML AbstractJMJD3, a stress-inducible H3K27 demethylase, plays a critical regulatory role in the initiation and progression of malignant hematopoiesis. However, how this histone modifier affects in a cell type-dependent manner remains unclear. Here, we show that in contrast to its oncogenic effect in preleukemia state and lymphoid malignancies, JMJD3 relieves the differentiation-arrest of certain subtypes (such as M2 and M3) of acute myeloid leukemia (AML) cells. RNA sequencing and ChIP鈭扨CR analyses revealed that JMJD3 exerts anti-AML effect by directly modulating H3K4 and H3K27 methylation levels to activate the expression of a number of key myelopoietic regulatory genes. Mechanistic exploration identified a physical and functional association of JMJD3 with C/EBP尾 that presides the regulatory network of JMJD3. Thus, the leukemia regulatory role of JMJD3 varies in a disease phase- and lineage-dependent manner, and acts as a potential oncorepressor in certain subsets of AML largely by coupling to C/EBP尾-centered myelopoietic program. IntroductionClassic transcription factors (TFs) associate with histone and DNA modifiers to regulate the transcriptional activation or repression of their specific target genes1. Jumonji domain-containing protein D3 (JMJD3) (also named KDM6B) is a family member of the histone H3 lysine 27 tri-methyl (H3K27me3)-specific demethylases that promote gene transcription mainly by acting as the rivals of the polycomb repressive complex 2 (PRC2) that otherwise catalytically add the methyl groups to H3K272,3. In addition, JMJD3 also associates with H3K4 methyltransferase complex to activate gene transcription and other transcriptional co-activators such as SWI/SNF complex to facilitate the transcriptional elongation across the H3K27me3-marked gene body in an enzyme activity-independent manner4,5,6.Interestingly, unlike another H3K27 demethylase UTX that is constitutively expressed in many types of tissue cells2,7, JMJD3 expression is highly inducible by stressful or pathogenic factors including inflammatory cytokines, mitochondrial and oncogenic stress inducers, and by certain normal developmental cues3,8. For example, Jmjd3, as induced by lipopolysaccharides聽(LPS), amyloid and granulocyte-macrophage colony-stimulating factor (GM-CSF), is globally involved in the transcriptional activation of inflammatory genes in M1 macrophages by counteracting the effect of PRC29,10,11,12. Jmjd3 is also required for M2 macrophage polarization during the innate immunity response against helminth infection13, and involved in TLR2-mediated foamy macrophage formation14.In the aspect of malignant hematopoiesis, an abnormally elevated JMJD3 level in association with an overactivated NF-魏b/innate immunity pathway was documented in human CD34+ hematopoietic stem/progenitor cells of the myelodysplastic syndrome (MDS)15, a preleukemic state that may evolve into acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL). Analogous to this, an oncogenic activity of JMJD3, deeply in association with its role in regulating immune cell differentiation and immunological responses16,17, is well documented in lymphoid malignancies18,19,20. Specifically, an oncogenic activity of JMJD3 in the NOTCH1-driven human T-cell acute lymphocytic leukemia (T-ALL) was described21. Mechanistically, the NF-魏b-induced JMJD3 overexpression in T-ALL cells was found to be essentially associated with NOTCH1 to activate the expression of T cell-specific oncogenic target genes. Nevertheless, what role JMJD3 plays in the maintenance of AML malignancy, probably through collaborating with certain emergency myelopoietic TFs, remains unclear.ResultsJMJD3 expressional reduction is correlated with poor prognosis in certain subtypes of AML casesTo understand a possible role of JMJD3 in AML, we firstly explored the NCBI GEO database and also examined the primary bone marrow (BM) samples of 74 AML patients we collected (Supplementary Data聽1) to determine whether an abnormal JMJD3 expression existed. In both BM and peripheral blood (PB) mononuclear samples, JMJD3 mRNA level was significantly reduced in AML blasts compared to normal subjects (Fig.聽1a, b). Particularly, the reduction in JMJD3 mRNA level was most prominent in AML subtypes including M1, M2 (M2 without AML-ETO (AE) fusion protein), M2b (M2 with AE fusion protein), and M3 that show immature features of granulocytic progenitors (Fig.聽1c). Consistently, western blotting assay in eight representative AML BM blast samples and seven AML cell lines across M2 to M6 subtypes indicated that among the common AML subtypes, a sharp decrease in JMJD3 protein level most likely occurred in M2 and M3 subtypes, and that among M4 or M5 subtypes, a moderate reduction was not consistently detected (Fig.聽1d, e). To test whether different doses of JMJD3 play a role in AML pathogenesis, we examined a possible association between the JMJD3 mRNA expression level and the overall survival in a cohort of AML patients from datasets of Verhaak and colleagues22. We observed that the survival of patients was positively associated with the JMJD3 expression level of leukemic blasts, especially in granulocytic subtypes, including M0鈥揗3 but not in monocytic-related subtypes (Fig.聽1f, h). Taken together, these results indicate that in contrast to the elevated expression of JMJD3 in MDS or T-ALL cells where it plays an oncogenic role15,21, a diminished JMJD3 expression in granulocytic subtypes of AML cells was associated with poor prognosis.Fig. 1JMJD3 expressional reduction is correlated with poor prognosis in certain subtypes of AML cases. a JMJD3 mRNA levels in BM and PB mononuclear cells of AML patients (including seven BM or 19 PB samples) and in normal counterparts (ten BM and ten PB samples) were compared (raw data retrieved from GEO (GSE9476) dataset). Boxes denote interquartile range, with a line at the median, while whiskers are indicating minimal and maximal observations for each parameter. b qRT-PCR assay on the JMJD3 mRNA level in the AML blasts-enriched primary BM mononuclear cells (n鈥?鈥?4) or normal BM mononuclear cells (n鈥?鈥?). c qRT-PCR assay on the JMJD3 mRNA level in the AML blasts-enriched primary BM mononuclear cells including subtype M1 (n鈥?鈥?), M2-AML1/ETO (鈭? (n鈥?鈥?0), M2-AML1/ETO (+) (n鈥?鈥?), M3 (n鈥?鈥?0), M4 (n鈥?鈥?5), M5 (n鈥?鈥?8), M6 (n鈥?鈥?) or normal BM mononuclear cells (n鈥?鈥?). d Western blotting assay on JMJD3 protein levels of eight AML blasts-enriched primary BM mononuclear cell samples, a normal BM mononuclear cell sample, and a T-ALL blasts-enriched BM mononuclear cell sample. 尾-actin level was used as the loading control. e Western blotting assay on JMJD3 protein levels of the established leukemia cell lines. f鈥?b>h Overall survival of AML patient cohort (f), M0, M1, M2, and M3 AML patient cohort (g), or M4 and M5 AML patient cohort (h) with regard to JMJD3 mRNA levels. Data are shown as the mean鈥壜扁€塖EM; *p鈥?lt;鈥?.05, **p鈥?lt;鈥?.01, ***p鈥?lt;鈥?.001Full size imageJMJD3 bears oncorepressor activity in mouse AML modelsNext, we employed three mouse AML models including one granulocytic M2b subtype expressing a human AML1-ETO9a (AE9a) fusion protein and one granulocytic M3/APL subtype expressing PML-RAR伪 (PR) fusion protein as well as one monocytic M5 subtype expressing MLL-AF9 (MF9) fusion protein to test whether JMJD3 possessed a genuine oncorepressor potential in AML23,24,25. Consistent with the observations made in human AML cells (Fig.聽1c, e), Jmjd3 mRNA and protein levels in the BM blasts of M2b model and M3 model were greatly decreased compared to normal counterparts, while Jmjd3 mRNA and protein levels in M5 blasts were only moderately reduced (Fig.聽2a, b). The genomic browser tracks of the chromatin immunoprecipitation sequence (ChIP-seq) analyses in human M2b Kasumi cells, M3/APL NB4, and UPR9 cells, and M5 MLL-AF9 cells26,27,28 indicated that AE or PR fusion protein occupied the gene locus of JMJD3 while MF9 did not (Supplementary Fig.聽1a), implicating JMJD3 as a direct target of the oncogenic proteins for two granulocytic subtypes. Accordingly, the introduction of the AE or PR but not MF9 into the normal mouse c-Kit+ BM progenitors immediately decreased the Jmjd3 mRNA level (Fig.聽2c).Fig. 2JMJD3 bears oncorepressor activity in mouse AML models. a, b聽Western blotting (a) or qRT-PCR (b) assay on Jmjd3 protein or mRNA level of GFP+ murine AML BM myeloid cell samples expressing PML-RAR伪, AML1-ETO9a, or MLL-AF9, and a normal sorted CD11b+ BM myeloid cell sample. c AML1-ETO, PML-RAR伪, or MLL-AF9 was transduced into normal c-Kit+ BM cells by retroviral infection, and the mRNA level of JMJD3 of the transduced GFP+ cells was measured by qRT-PCR. d Experimental protocol for testing the in vivo proliferative capacity of GFP+ BM leukemic cells transduced with YFP+ vector control or JMJD3-expressing vector in FVB/NJ or C57BL/6J mice. e GFP+ murine AML BM cells expressing PML-RAR伪, AML1-ETO9a, or MLL-AF9 were transduced with YFP+ empty vector or JMJD3-expressing vector, and the mRNA levels of mouse Jmjd3 or human JMJD3 were measured by qRT-PCR. f The percentages of PML-RAR伪 (left panel) or AML1-ETO9a (right panel) GFP+YFP+ cells in the peripheral blood of syngeneic recipients after they had been transduced with YFP+ empty vector or JMJD3-expressing vector. g Kaplan鈥揗eier curves are shown for syngeneic mice transplanted with GFP+ AML (left panel, PML-RAR伪+ cells; right panel, AML1-ETO9a+ cells) BM cell transduced with YFP+ empty vector or JMJD3-expressing vector. h The percentages of MLL-AF9+ GFP+YFP+ cells in the peripheral blood (left panel) and the survival (right panel) of the syngeneic recipients transduced with YFP+ empty vector or JMJD3-expressing vector. i, j Flow cytometric analyses of Gr-1 expression (i) or CD11b expression (j) on PML-RAR伪+ (left panel) or AML1-ETO9a+ (right panel) leukemia BM cells transduced with YFP+ empty vector or JMJD3-expressing vector and cultivated for 72鈥塰. k Flow cytometric analyses of Annexin V staining on PML-RAR伪+ (left panel) or AML1-ETO9a+ (right panel) leukemia BM cells transduced with YFP+ empty vector or JMJD3-expressing vector. l鈥?b>n Flow cytometric analyses of Gr-1 expression (l), CD11b expression (m), or Annexin V staining (n) on MLL-AF9+ BM cells transduced with YFP+ empty vector or JMJD3-expressing vector in vivo. Data are shown as the mean鈥壜扁€塖EM; *p鈥?lt;鈥?.05, **p鈥?lt;鈥?.01, ***p鈥?lt;鈥?.001Full size imageThen we lentivirally transduced the primary leukemic blastic BM samples with empty vector or JMJD3 expression cassette in a short-term culture, and transplanted the purified transduced GFP+YFP+ AML cells into the syngeneic recipients (Fig.聽2d). JMJD3 overexpression potently inhibited the in vivo repopulation of two granulocytic subtypes of AML cells (Fig.聽2e, f and Supplementary Fig.聽1b), and greatly elongated the recipients鈥?survival (Fig.聽2g). Virtually, deaths of a few recipients were from the outgrowth of GFP+YFP鈭?/sup> leukemia cells that did not express JMJD3 (Supplementary Fig.聽1c). On the other hand, JMJD3 overexpression only moderately inhibited the repopulation kinetics of M5 cells in vivo (Fig.聽2h and Supplementary Fig.聽1d). The cellular mechanistic analyses of the in vitro cultivated M2b and M3 cells and in vivo retrieved M5 cells indicated that JMJD3 exerted strong differentiation- and apoptosis-induction effects in M3 model, a strong apoptosis-induction effect in M2b model, and moderate differentiation- and apoptosis-induction effects in M5 model (Fig.聽2i, n and Supplementary Fig.聽1e, j). Therefore, JMJD3 exerts a potential anti-AML activity in a subtype and oncogenic fusion protein-dependent manner.JMJD3 exhibited anti-human AML activity in a demethylase-dependent mannerIn accordance with its role in mouse AML models, the lentiviral vector-delivered JMJD3 expression-cassette resulted in JMJD3 overexpression and decreased the colony-forming potential of the primary leukemic blasts in six out of seven cases (in one M2b, one M3, two M4, and one unclassified AML case but only in one out of two M5 cases) (Fig.聽3a and Supplementary Fig.聽2a). Likewise, JMJD3 overexpression showed myeloid differentiation-induction and apoptosis-induction effect in one M2 (without AE), three M3/APL, two M4, and one or two out of three M5 human primary blastic BM samples (Fig.聽3b, c and Supplementary Fig.聽2b, d). Nevertheless, JMJD3 knockdown in five primary AML blastic samples (one M2 without AE, one M3, one M4, and two M5) decreased CD11b level in four cases except one M5 but not significantly influenced their survival status (Supplementary Fig.聽2e, h), indicating a genuine regulatory role of JMJD3 on the differentiation status of AML blasts.Fig. 3JMJD3 exhibited anti-human AML activity in a demethylase-dependent manner. a The number of the leukemic colony forming units for seven primary AML blast samples transduced with control vector or JMJD3-expressing vector. b, c Flow cytometric analyses of CD11b expression (b) or Annexin V staining (c) on ten primary AML blast samples transduced with control vector or JMJD3-expressing vector. d Flow cytometric analyses of CD11b expression on six AML cell lines transduced with control vector or JMJD3-expressing vector. e Western blotting assay on JMJD3 protein in HL-60 cells transduced with vector control, JMJD3-, or H1390A mutant-expressing vector (upper panel), and in parental and JMJD3 KO HL-60 cell lines (bottom panel). f鈥?b>h Flow cytometric analyses of CD11b expression (f), Annexin V staining (g), and cell cycles (h) in HL-60 cells transduced with vector control, JMJD3-, or H1390A mutant-expressing vector, or in parental or JMJD3 knockout HL-60 cells. i Experimental protocol for testing the in vivo proliferative capacity of HL-60 cells transduced with vector control, JMJD3-, or H1390A mutant-expressing vector in NOD/SCID mice; 5鈥壝椻€?06 transduced GFP+ HL-60 cells were intravenously transplanted into each NOD/SCID mouse. j qRT-PCR assay on the JMJD3 mRNA level of GFP+ HL-60 cells isolated from the BM at 35 days after transplantation. k The percentages of GFP+ cells in BM, spleen, liver, and PB at 35 days after transplantation. l Kaplan鈥揗eier survival curves of NOD/SCID mice injected with HL-60 cells transduced with vector control, JMJD3-, or H1390A mutant-expressing vector; p鈥?鈥?.0003 (blue), vector versus JMJD3; p鈥?鈥?.0011 (purple), H1390A versus JMJD3. Data are shown as the mean鈥壜扁€塖EM; *p鈥?lt;鈥?.05, **p鈥?lt;鈥?.01, ***p鈥?lt;鈥?.001Full size imageStrikingly, a JMJD3 overexpression-induced CD11b expression was prominent in a M2/M3 cell line HL-60 (without AE and PR) and NB4 cell line (with PR) as compared to that detected in M2b Kasumi cells, all-trans retinoid acid (ATRA)-resistant M3 NB4-R2 cells, and M5 THP-1 (with MF9) and U937 cells, whereas apoptosis-induction effect was apparent in all tested cell lines except U937 cells (Fig.聽3d and Supplementary Fig.聽3a, b). Thereafter, we mainly used HL-60 cells or/and NB4 cells to further characterize the relevant mechanisms of JMJD3 in regulating AMLs. As evidenced by western blotting assay and flow cytometric analyses of myeloid differentiation antigen CD11b expression, cell survival, and cell cycle (Fig.聽3e, h and Supplementary Fig.聽3c, e), the forced expression of WT JMJD3 but not H1390 mutant or empty vector potently drove the myeloid differentiation of AML cells in a demethylase-dependent manner (by 50-fold), to be accompanied by the moderately reduced survival (by seven-fold) and proliferation of leukemia cell. Conversely, the JMJD3 knockout at least moderately hindered the CD11b expression of HL-60 (Fig.聽3e, h and Supplementary Fig.聽3c, e). Critically, the overexpression of JMJD3, but not the empty vector or a catalytically inactive JMJD3 mutant (H1390A), prolonged the survival of the NOD/SCID mouse recipients intravenously inoculated with the transduced GFP+ HL-60 cells (Fig.聽3i, l). As expected, the much more GFP+ leukemia cells were readily detected in BM, spleen, liver, and PB of the mice transplanted with leukemia cells harboring the empty vector or overexpressing H1390A but not with leukemia cells overexpressing JMJD3 (Fig.聽3k and Supplementary Fig.聽3f). Overall, these observations demonstrated a potential oncorepressor activity of JMJD3 enzyme in vivo and in vitro in the setting of certain subtypes of AML such as M2 and M3, which was most likely in association with the forced myeloid differentiation as well as the reduced survival and proliferation of AML blasts.JMJD3 induces the expression of key myelopoietic regulators in human AML cellsThe demethylase activity-dependent suppressing role of JMJD3 in HL-60 cells indicated that this effect was largely executed through the modulation of the transcriptional program of AML cells. Therefore, we explored the JMJD3 overexpression- and JMJD3 knockout-caused mRNA expressional alterations to identify the responsible target genes (Supplementary Data聽2鈥?a data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"/articles/s41467-018-05548-z#MOESM5\">3). In agreement with the documented role of JMJD3 as a transcriptional co-activator, RNA sequencing (RNA-seq) showed that the number of the upregulated genes versus that of the downregulated ones by JMJD3 overexpression in HL-60 cells was 1639:318 (Fig.聽4a). In line with the previous observation29,30, the gene set enrichment analysis (GSEA) revealed significant enrichment of senescence genes and P53 pathway genes in JMJD3-overexpressed HL-60 cells (Fig.聽4b, c). Nevertheless, the transcription of INK4a-ARF locus was not altered by JMJD3 overexpression (Supplementary Fig.聽4a)29. Albeit the signatures of inflammatory response and innate immunity pathways were enriched in JMJD3-overexpressed HL-60 cells (Fig.聽4d and Supplementary Fig.聽4b), JMJD3 overexpression did not elevate the mRNA level of P65 subunit of NF-魏B pathway or those of NOTCH1 targets HEY1 and HES5 (Fig.聽4e and Supplementary Fig.聽4c, e)15,21. Interestingly, JMJD3 overexpression also negatively regulated the expression of a leukemia stem cell (LSC) gene signature and that of a hematopoietic early progenitor gene signature (Fig.聽4f and Supplementary Fig.聽4f left panel). Conversely, JMJD3 overexpression positively modulated the expression of the gene signatures of the myeloid development and mature hematopoietic cells (Fig.聽4g and Supplementary Fig.聽4f right panel). GSEA also showed a positive enrichment for the gene signature associated with apoptosis, and a negative enrichment for the gene signature associated with cell cycle in JMJD3-overexpressed HL-60 cells (Supplementary Fig.聽4g, h). Likewise, gene ontology (GO) analyses revealed that the genes upregulated upon JMJD3 overexpression were enriched in functional categories linked to hematopoietic differentiation and apoptosis (Supplementary Fig.聽4i). Similarly, JMJD3 overexpression in NB4 cells downregulated the expression of the LSC gene signature, the hematopoietic early progenitor signature and the cell cycle signature, but upregulated the expression of the mature hematopoietic cell signature without activating the pathways of senescence, innate immunity, NF-魏B, or the NOTCH1 targets HEY1 and HES5 (Supplementary Fig.聽4j, r). In line with the observations mentioned above (Fig.聽3), these analyses confirmed that the enhanced myeloid differentiation, in companion of the suppressed LSC program but not聽the enhanced apoptosis and cell cycle arrest, represented the major effector pathways of JMJD3 overexpression in AML cells.Fig. 4JMJD3 induces the expression of key myelopoietic regulators in AML cells. a Heatmap showing the differentially expressed genes between HL-60 cells transduced with control or JMJD3-expressing vector (fold change 鈮?, p鈥?lt;鈥?.05). b鈥?b>g GSEA of the expressing profile of HL-60 cells transduced with control or JMJD3-expressing vector using a senescence-associated upregulated signature (b), a p53 pathway-associated signature (c), an innate immune system-associated signature (d), a NF-魏B pathway-associated signature (e), a leukemic stem cell (LSC)-associated upregulated or downregulated signature (f), and a myeloid cell development-associated upregulated or downregulated signature (g). h Differential expression analyses of HL-60 cells upon overexpression of JMJD3 (fold change 鈮?, p鈥?lt;鈥?.05) (top panel), and validation of the mRNA levels of a number of genes by qRT-PCR (bottom panel). FPKM, fragments per kilobase of transcript per million fragments mapped. i Differential expression analysis upon knockout of JMJD3 in HL-60 (fold change 鈮?.5, p鈥?lt;鈥?.05) (top panel), and validation of the mRNA levels of a number of genes by qRT-PCR (bottom panel). j Two primary AML blasts and the NB4 cells were transduced with empty vector or JMJD3-expressing vector, and the mRNA levels of C/EBP尾 or RIPK3 were measured by qRT-PCR. k NOD/SCID mice injected with HL-60 cells transduced with vector control, JMJD3-, or H1390A mutant-expressing vector, and qRT-PCR assay on the C/EBP尾 or RIPK3 mRNA level of GFP+ HL-60 cells isolated from the BM at 35 days after transplantation. l GFP+ murine AML BM cell samples from PML-RAR伪-, AML1-ETO-, or MLL-AF9-expressing transgenic mice were transduced with empty vector or JMJD3-expressing vector, and the mRNA levels of C/EBP尾 or RIPK3 were measured by qRT-PCR. m Correlated mRNA levels of C/EBP尾 or RIPK3 with those of JMJD3 in 179 AML patients (raw data from TCGA database). n鈥?b>p HL-60 cells transduced with vector control or JMJD3-expressing vector were further treated with NC siRNA, C/EBP尾 siRNA, or RIPK3 siRNA. Flow cytometric analyses of CD11b expression (n), annexin V staining (o), and cell cycle status (p). Data are shown as the mean鈥壜扁€塖EM; *p鈥?lt;鈥?.05, **p鈥?lt;鈥?.01, ***p鈥?lt;鈥?.001Full size imageAs expected, JMJD3 overexpression or JMJD3 knockout in HL-60 cells altered the mRNA levels of a number of key regulators of myeloid differentiation, apoptosis/senescence, cell cycle and innate immunity in a reverse way, which was confirmed by quantitative polymerase chain reaction (qPCR) assays (Fig.聽4h, i). The overlapping of these two pools identified two highly sensitive responsive genes: C/EBP尾鈥攁 key TF-mediating emergency myelopoiesis, and RIPK3鈥攁 key suppressor of AML malignancy through activating IL-1尾-related innate immunity pathway31,32,33,34. In agreement, JMJD3 overexpression upregulated the C/EBP尾 mRNA level in human AML cells cultivated in vitro or HL-60 cells repopulated in the NOD/SCID mice as well as in three subtypes of mouse AML cells, and also the RIPK3 mRNA level in these cells except NB4 cells, the mouse M3/APL cells and the mouse M5 cells expressing MF9 (Fig.聽4j, l and Supplementary Fig.聽4s). The in silico analysis showed that JMJD3 mRNA level was positively correlated with C/EBP尾 or RIPK3 mRNA level among primary AML blast samples (Fig.聽4m), indicating that the regulation of C/EBP尾 or RIPK3 by JMJD3 was generally present in AML cells. Moreover, C/EBP尾 or RIPK3 knockdown exerted a reversing effect on the JMJD3 overexpression-induced myeloid differentiation, cell death, and cell cycle arrest, with C/EBP尾 showing a stronger effect than RIPK3 (Fig.聽4n, p and Supplementary Fig.聽4t, x). Taken together, these results indicated that C/EBP尾 and RIPK3 represent two major targets of JMJD3 to mediate the myeloid differentiation, cell cycle arrest, and cell death of AML blasts.JMJD3 regulates dynamic H3K4me3 and H3K27me3 modifications in the promoter of myelopoietic genesThen we performed ChIP-seq and ChIP鈥搎PCR assays to compare the possible alterations in H3K4me3 and H3K27me3 of the JMJD3-regulated genes after JMJD3 knockout in HL-60 cells. The JMJD3 loss globally reduced the H3K4me3 abundance but increased the H3K27me3 abundance around numerous promoters in HL-60 cells (Fig.聽5a). As expected, most of the downregulated genes in the JMJD3鈭?鈭?/sup> HL-60 cells were in association with a reduced H3K4me3 but an increased H3K27me3 around the promoter within 3鈥塳b upstream or downstream of the transcription start site (TSS) (Fig.聽5b). As shown by the genomic browser tracks and validated by ChIP鈥搎PCR, the reduced H3K4me3 and increased H3K27me3 were evident around the promoters of the key myelopoietic regulators such as C/EBP尾, IER3, CCNG2, and SPRY4 as well as the innate immunity component such as RIPK3 and ICAM1, but not in the gene locus of IFNB1 that serves as a negative control of JMJD3 target genes (Fig.聽5c, e and Supplementary Fig.聽5a, c. See also Fig.聽4i). In parallel, ChIP鈥搎PCR assay on the potential JMJD3-binding sites, where the H3K27me3 abundance was significantly altered in JMJD3鈭?鈭?/sup> HL-60 cells, showed that JMJD3 knockout removed the occupancy of JMJD3 (Fig.聽5f). These results indicated that a number of myelopoietic regulators and innate immunity components in AML cells belonged to the direct target genes of JMJD3. Expectedly, JMJD3 overexpression increased H3K4me3 but decreased H3K27me3 around these potential JMJD3-occupying sites (Fig.聽5g, h and Supplementary Fig.聽5d, e).Fig. 5JMJD3 regulates dynamic H3K4me3 and H3K27me3 modifications in the promoter of myelopoietic genes. a Box plots showing the differences of H3K4me3 (left) and H3K27me3 (right) occupancies around the promoter (with 3鈥塳b upstream or downstream of the TSS) of parental and JMJD3 knockout HL-60 cells. b The loci of the downregulated genes in JMJD3 deficiency exhibit a decrease in H3K4me3 (blue dots, left panel) but an increase in H3K27me3 level (red dots, right panel). FPKM, fragments per kilobase of transcript per million fragments mapped. c Genome browser tracks representing the binding sites of H3K4me3 and H3K27me3 at the C/EBP尾 or RIPK3 gene locus in parental and JMJD3 knockout HL-60 cells. d, e ChIP鈥搎PCR assay for H3K4me3 (d) and H3K27me3 (e) at the C/EBP尾, RIPK3 or IFNB gene locus in parental and JMJD3 knockout HL-60 cells. f ChIP鈥搎PCR assay for JMJD3 occupancy at a number of gene loci in parental and JMJD3 knockout HL-60 cells. g, h ChIP鈥搎PCR assay for H3K4me3 (g) and H3K27me3 (h) at the C/EBP尾 or RIPK3 gene locus in HL-60 cells transduced with empty vector or JMJD3-expressing vector. Data are shown as the mean鈥壜扁€塖EM; *p鈥?lt;鈥?.05, **p鈥?i> 鈥?.01Full size imageJMJD3 upregulates and partners with C/EBP尾 to regulate the expression of key myelopoietic regulators in AML cellsThen we sought for the principal TFs that recruited JMJD3 to the regulatory regions of these key myelopoietic regulators, P53鈥揚21 axis, and innate immunity components. Interestingly, GSEA exhibited an enrichment of C/EBP尾-bound promoter targets in JMJD3-overexpressed HL-60 cells (Fig.聽6a). Besides, we did an analysis of the promoter targets of C/EBP尾 in HL-60 cells by ChIP-seq (Supplementary Data聽4), and noticed that about 1/3 of JMJD3-upregulated genes were also the direct target genes of C/EBP尾, displaying a significant correlation (p鈥?鈥?.49鈥壝椻€?0鈭?, Fig.聽6b). Interestingly, the enhanced expression of these C/ebp尾 target genes was also recapitulated in the mouse AML cells when JMJD3 was overexpressed (Fig.聽6c and also see Fig.聽4l). Specifically, these overlapped genes included C/EBP尾 and JMJD3 themselves, other myelopoietic regulators and innate immunity components such as JUNB, IER3, CCNG2, SPRY4, ICAM1, P53-P21 axis, IL-1尾, and S100A9 (but not RIPK3) (Fig.聽6b, d, e and Supplementary Fig.聽6a, b), thus indicating C/EBP尾 as one of the principle TFs that recruited JMJD3 to the target promoters and the existence of a positive feedback mechanism of JMJD3 regulatory effect through activating C/EBP尾 expression in AML cells. In support of this, C/EBP尾 knockdown almost abolished the occupancy of JMJD3 on the promoter of these target genes (Fig.聽6f and Supplementary Fig.6c), and significantly dampened the mRNA-elevating effect of JMJD3 on these genes (Fig.聽6g). Consistently, C/EBP尾 overexpression in HL-60 cells elevated the mRNA levels of the same set of target genes (except RIPK3) as regulated by JMJD3 (Fig.聽6h). Moreover, knockdown of JUNB, a potent oncorepressor of myeloid leukemia35,36, at least partially mimicked the role of C/EBP尾 knockdown in reversing the differentiation-promoting effect of JMJD3 overexpression (Supplementary Fig.聽6d, e). On the other hand, RIPK3 knockdown dampened the JMJD3 overexpression-induced upregulation of C/EBP尾, IL-1尾, and S1009A but not JMJD3 itself, indicating an upstream role of RIPK3 in facilitating C/EBP尾 induction or activation (Fig.聽6i). Collectively, these observations suggested a nodal role of the C/EBP尾 and JMJD3 partnership in mediating the AML-suppressing effect of JMJD3. Verifying this, C/EBP尾 knockdown significantly restored the colony forming capacity of HL-60 cells as repressed by JMJD3 overexpression (Fig.聽6j, l).Fig. 6JMJD3 upregulates and partners with C/EBP尾 to regulate the expression of key myelopoietic genes in AML cells. a GSEA of the expressing profile of HL-60 cells transduced with control or JMJD3-expressing vector using a C/EBP尾 target genes-associated signature. b Venn diagram showing the overlap between C/EBP尾 promoter targets in C/EBP尾-overexpressed HL-60 cells (red, see also Supplementary Data聽4) and the upregulated genes in JMJD3-overexpressed HL-60 cells (gray, see also Supplementary Data聽2) with a p value calculated by hypergeometric test. c GFP+ murine AML BM cell samples from PML-RAR伪- (upper panel), AML1-ETO9a- (middle panel), or MLL-AF9- (low panel) expressing transgenic mice were transduced with an empty vector or JMJD3-expressing vector, and the mRNA levels of a number of genes were measured by qRT-PCR. d Genome browser tracks representing the binding sites of C/EBP尾 at the C/EBP尾, JUNB, JMJD3 or IFNB1 gene locus. e ChIP鈥搎PCR assay for C/EBP尾 or IgG occupancy at the C/EBP尾, JUNB, JMJD3 or IFNB1 gene locus in C/EBP尾-overexpressed HL-60 cells. f ChIP鈥搎PCR assay for JMJD3 occupancy at the C/EBP尾, JUNB, JMJD3 or IFNB1 gene locus for NC or C/EBP尾 knockdown HL-60 cells transduced with control or JMJD3-overexpressed vector. g qRT-PCR assay on the mRNA levels of a number of genes when HL-60 cells were transduced with control or C/EBP尾-expressing vector. h qRT-PCR assay on the mRNA levels of a number of genes when JMJD3-overexpressed HL-60 cells were transduced with or without C/EBP尾 siRNA. i qRT-PCR assay on the mRNA levels of a number of genes when JMJD3-overexpressed HL-60 cells were transduced with or without RIPK3 siRNA. j鈥?b>l The number and typical pictures of the colonies for NC or C/EBP尾 knockdown HL-60 cells that had been transduced with control or JMJD3-overexpressing vector. m 32D cell lysates were immunoprecipitated with Jmjd3 antibody and subsequently subjected to western blot with Jmjd3, C/ebp伪 or C/ebp尾 antibody: IgG served as negative IP control. n Heatmap representation of C/ebp尾 and Jmjd3 tag density centered on C/ebp尾 ChIP-seq peaks in 32D cells. Data are shown as the mean鈥壜扁€塖EM; *p鈥?lt;鈥?.05, **p鈥?lt;鈥?.01, ***p鈥?lt;鈥?.001Full size imageSimilar to what we observed in the expressional regulation of JMJD3 in AML cells, C/EBP尾 mRNA level was decreased in primary AML blasts compared to normal counterparts (Supplementary Fig.6f), and ChIP-seq analysis of AML cells and transfection experiment of normal c-Kit+ BM progenitors indicated that the transcription of C/EBP尾 was likely repressed by oncogenic proteins such as PML-RAR伪 (Supplementary Fig. 6g, h). Nevertheless, in murine non-malignant myeloid progenitor cell line 32D cells, the expressions of C/ebp尾 and Jmjd3 were readily detectable by western blotting. As expected, co-immunoprecipitation (co-IP) assay showed that endogenous Jmjd3 physically associated with C/ebp尾 but not C/ebp伪, another major myeloid TF (Fig.聽6m), which was confirmed by co-IP assay of 293T cells expressing human C/EBP尾 and JMJD3 (Supplementary Fig.聽6i). Virtually, ChIP-seq profiling of C/ebp尾 and Jmjd3 binding sites across the genome of 32D cells revealed that C/ebp尾 and Jmjd3 were highly correlated on intergenic and intragenic regions, suggesting that C/ebp尾 and Jmjd3 coregulate the expression of a great number of genes potentially transcribed in the non-malignant myeloid progenitors (Fig.聽6n). Taken together, these results indicated that the regulatory activity of JMJD3 during myelopoiesis was at least partially accomplished by forming a special partnership with C/EBP尾 in which the autocrine induction of these two genes by either of them may rapidly bring about a strong anti-AML effect.C/EBP尾/JMJD3 induction participates in ATRA-induced myeloid differentiation of AML cellsATRA-induced myeloid differentiation of multiple subtypes of AML cells (especially M2 and M3/APL subtypes) inhibits their leukemogenic potential in patients and in patient-derived xenografting models37,38. C/EBP尾 induction has been shown to participate in the ATRA-induced myeloid differentiation of AML cells39, while what epigenetic factor(s) cooperated with C/EBP尾 in effecting myeloid differentiation remained unclear. In line with the above observations that C/EBP尾 partnered with JMJD3, upon the forced JMJD3 overexpression, to regulate the myeloid differentiation program of AML cells, western blotting assay showed that ATRA induced a significant induction of JMJD3 in parallel to the induction of C/EBP尾 in HL-60 cells, and that JMJD3 deficiency compromised the ATRA-induced C/EBP尾 upregulation and myeloid differentiation (Fig.聽7a, b). As expected, co-IP and ChIP鈥搎PCR assays on C/EBP尾 locus demonstrated that ATRA signaling enhanced the C/EBP尾/JMJD3 association and their occupancy on C/EBP尾 promoter (Fig.聽7c, d).Fig. 7C/EBP尾/JMJD3 induction participates in ATRA-induced myeloid differentiation of AML cells. a HL-60 cells were treated with 1鈥壜礛 ATRA for the indicated times. The protein levels of C/EBP尾, JMJD3, and C/EBP伪 were measured by western blotting, and 尾-actin was used as a loading control. b Flow cytometric analyses of CD11b expression of HL-60 parental cells or JMJD3 knockout HL-60 cells treated with or without 1鈥壜礛 ATRA for 48鈥塰. c Hl-60 cells were treated with 1鈥壜礛 ATRA for 48鈥塰. Cell lysates were then co-immunoprecipitated with JMJD3 antibody, C/EBP尾 antibody or control IgG, to be followed by immunoblot with anti-C/EBP尾 or anti-JMJD3 antibody as indicated. d ChIP鈥搎PCR for JMJD3 or C/EBP尾 occupancy at the C/EBP尾 gene locus for HL-60 cells treated with or without 1鈥壜礛 ATRA for 24鈥塰. Data are shown as the mean鈥壜扁€塖EM; *p鈥?lt;鈥?.05, **p鈥?lt;鈥?.01Full size imageDiscussionIn the case of T-ALL and MDS, an oncogenic role of JMJD3 has been well documented, which was largely attributed to its specific partnership with NF-魏B and NOTCH15,21, two TFs whose overactivations are highly associated with the induction of multiple types of inflammatory cytokines and the proliferation of T cells3,40. On the other hand, although JMJD3 is well-documented to mediate the oncogenic stress-induced cell senescence via activating INK4 gene locus (INK4b-ARF-INK4a) and/or facilitating the regulatory activity of P53 on its target genes in non-malignant fibroblasts29,30,41,42,43, a corresponding oncorepressor activity of JMJD3 in human malignancies via cell senescence induction has not been established. Virtually, it was recently shown that JMJD3-induced INK4a/P16 expression was beneficial to the survival of cervical carcinoma cells44. Nevertheless, JMJD3 deficiency was reported to promote malignant progression of human pancreatic carcinoma by decreasing the expression of C/EBP伪, a potential inhibitory partner of E2F145,46. Moreover, an elevated H3K27me3 level in association with JMJD3 insufficiency promoted the dedifferentiation of hypoxic V600EBRAF melanoma cells and rendered them resistant to BRAF inhibitor47. These observations implicate the existence of uncharacterized regulatory effects of JMJD3 on cell differentiation, survival, and proliferation, whose deficiency contributes to the carcinogenesis in a tumor cell type-dependent manner.How the origin and progression of malignant myelopoiesis are associated with the C/EBP尾-centered myelopoietic program is an unsolved issue48,49,50. In this study, we provide evidence that repression of C/EBP尾/JMJD3 partnership probably represents an essential oncogenic event for the maintenance of leukemic malignancy in certain subtypes of AML (mostly M2 and M3), and their overexpression drives these AML cells to undergo myeloid differentiation and lose their capacity to re-establish leukemia in vivo. In this regard, in parallel to the observation that JMJD3 expression is highly inducible by ATRA51, C/EBP尾 has been shown to mediate ATRA-induced differentiation of AML cells39,52, and to suppress the malignancy of chronic myeloid leukemia blasts by inducing their myeloid maturation53,54. Moreover, in parallel to the fact that JMJD3 in myeloid cells is highly inducible during innate-immunity response3, C/EBP尾 has been shown to specifically participate in the innate immunity-related emergency myelopoiesis but not the steady myelopoiesis31,55. Likewise, a few major components of innate immunity response such as TLR8 and IRF8 have been shown to modulate the malignant origin and maintenance of AML cells56,57. Furthermore, the progenitors of emergency myelopoiesis were recently shown to share the same clustering proliferative feature with the malignant myeloid blasts58. Taken together, these observations implicate a possible regulatory effect of emergency myelopoietic program on the maintenance of AML malignancy.In many types of inflammatory progression, the expression of JMJD3 is directly activated by the inflammatory TFs such as NF-魏b, Stat4/6, Atf-4 and Hif1; the induced JMJD3, in turn, functions as a major co-activator of these TFs in driving the transcriptional activation of numerous inflammatory genes, thus forming a positive feedback circuit facilitating the rapid induction of immunological response3. In a similar manner, we found that C/EBP尾 directly activated JMJD3 expression, which in turn couples to the regulatory effect of JMJD3 on numerous target genes such as JUNB, PU.1, P53-P21 axis and innate immunity components. Moreover, as mentioned above, the NF-魏b-centered activation of innate immunity pathways play a determining oncogenic role in MDS and T-ALL15,21. Nevertheless, this study also indicates that a JMJD3-mediated activation of innate immunity, as marked by the induction of RIPK3-IL-1尾 axis in a NF-魏B-independent manner within AML cells, is unfavorable for the maintenance of malignancy34.MethodsMiceNOD/SCID mice were purchased from Shanghai SLAC Laboratory Animal Co., Ltd., and were fed and maintained in accordance with the institutional guidelines for animals of Shanghai Jiao Tong University School of Medicine. All animal experiments were carried out in accordance with guidelines approved and provided by the Laboratory Animal Resource Center of Shanghai Jiao Tong University School of Medicine.Primary AML blasts samples, cell lines, and cell cultureHuman AML samples were obtained after receiving informed consents from the patients admitted to the Department of Hematology in Ruijin Hospital. BM leukemic blasts were isolated by Ficoll-Hypaque density gradient centrifugation and cultured with Isocove modified Dulbecco medium (IMDM) supplemented with 10% BIT (Stem Cell Technologies, Vancouver, Canada) for 5 days. Leukemic cell lines (HL-60, Kasumi-1, NB4, NB4-R2, THP-1, U937, K562, and Jurkat) were obtained from Cell Bank of Shanghai Institute of Hematology and cultured in RPMI-1640 medium (Invitrogen Corporation) supplemented with 10% FBS (Gibco-BRL) in 5% CO2 and humidified atmosphere at 37鈥壜癈. ATRA was purchased from Sigma-Aldrich.Western blottingTotal cell lysates or protein extracts were equally loaded on 8鈥?2% SDS-polyacrylamide gel for running and then transferred to polyvinylidene difluoride聽(PVDF) membranes (GE Healthcare-Amersham Biosciences, UK). After blocking with 5% non-fat milk in Tris buffered saline with Tween 20聽(TBST), the membranes were incubated for 2鈥塰 or overnight with the primary antibodies. After staining with horseradish peroxidase (HRP)-linked secondary antibodies, signal detection was performed using a chemiluminescence phototope-HRP Kit (Millipore). The band intensity was estimated using the Photoshop Software. Densitometric analysis was performed using ImageJ software (NIH, Bethesda, MD). The following antibodies were used: anti-JMJD3 (ab154126, Abcam, 1:250), anti-C/EBP尾 (sc-150脳, Santa Cruz, 1:1000), anti-C/EBP伪 (2843, Cell Signaling, 1:1000), anti-RIPK3 (ab56164, Abcam, 1:1000), anti-JUNB (3753S, Cell Signaling, 1:1000), anti-Flag (F7425, Sigma, 1:5000) and anti-Myc (9B11, Cell Signaling, 1:1000), and anti-尾-actin (A5316, Sigma, 1:5000).qRT-PCR and RNA-seqTotal cellular RNA was extracted using the RNeasy mini kit (QIAGEN) following the manufacturer鈥檚 instruction. The cDNA was synthesized through reverse transcription of 1鈥壩糶 of RNA using RevertAid First Strand cDNA Synthesis Kit (Thermo). Quantitative real-time PCR (qRT-PCR) was performed using a 7500 sequence detection system (Applied Biosystems) and SYBR Green Realtime PCR Master Mix (Toyobo). GAPDH was used as an internal control in qRT-PCR. Primer sequences for qRT-PCR are available in the Supplementary Data聽5.RNA samples were sequenced and analyzed by Shanghai Majorbio Biotechnology Co., Ltd. and Shanghai Jiayin Biotechnology Co., Ltd. RNA-seq transcriptome library was prepared following TruSeqTM RNA sample preparation Kit from Illumina (San Diego, CA) using 1鈥壩糶 of total RNA. Shortly, messenger RNA was isolated according to polyA selection method by oligo (dT) beads and then fragmented by fragmentation buffer firstly. Secondly, double-stranded cDNA was synthesized using a SuperScript double-stranded cDNA synthesis kit (Invitrogen, CA) with random hexamer primers (Illumina). Then the synthesized cDNA was subjected to end-repair, phosphorylation, and 鈥楢鈥?base addition according to Illumina鈥檚 library construction protocol. Libraries were size selected for cDNA target fragments of 200鈥?00鈥塨p on 2% Low Range Ultra Agarose followed by PCR amplified using Phusion DNA polymerase (NEB) for 15 PCR cycles. After quantified by TBS380, paired-end RNA-seq library was sequenced with the Illumina HiSeq 4000 (2鈥壝椻€?50鈥塨p read length). For bioinformatics analyses, raw sequence reads were initially processed using FastQC (Babraham Institute, Cambridge, UK) for quality control, and then adapter sequences and poor quality reads were removed using Cutadapt. Quality-filtered reads were then mapped to human genome (hg19) using STAR, and only the uniquely mapped reads were kept. Read counts were calculated using HTSeq-count. Differentially expressed genes were identified using R package DESeq2 (fold change 鈮?, p鈥?i> 鈥?.05 or fold change 鈮?.5, p鈥?i> 鈥?.05).ChIP and ChIP-seqChIP assays were performed according to the standard cross-linking ChIP protocol (Abcam) with minor modifications. Briefly, cells were harvested and crosslinked with 1% formaldehyde for 10鈥塵in at room temperature. After sonication, the soluble chromatins were incubated with specific antibodies. Chromatin immunocomplexes were then precipitated with Protein A (Millipore, 16-661) or Protein G (Millipore, 16-662). The immunoprecipitated complex was washed, and DNA was extracted and purified by QIAquick PCR Purification Kit (Qiagen). ChIP DNA was analyzed by qPCR using specific primers, and the data were normalized by input DNA. The results were derived from three independent experiments. The primers used for ChIP-qPCR are listed in Supplementary Data聽5. For ChIP-seq, extracted DNA was ligated to specific adaptors followed by deep sequencing in the Illumina HiSeq 2500 system as according to the manufacturer鈥檚 instructions. ChIP-seq data were aligned to the human genome (hg19) reference genome using bwa version 0.7.1059 with default parameter settings. Subsequently, reads were filtered for duplicates and extended by 200鈥塨p. Visualization of read count data was performed by converting raw bam files to bigwig files using IGV tools60 and normalized to 1 million reads. For the analysis of the ChIP-seq datasets, we utilized MACS2 peak caller version 2.1.1 to identify peaks. For peak calling, we used MACS (version 2.1.1) with the sonicated input as a control and an initial threshold q-value of 0.01 as cutoff. For C/EBP尾 ChIP-seq, signal for each gene was quantified as total number of reads per million in the region 3鈥塳b upstream of the TSS to 3鈥塳b downstream of the TSS. The bioinformatics analysis of ChIP-seq data was performed by Shanghai Jiayin Biotechnology Co., Ltd.co-IP assayThe cells were lysed in 1鈥塵l lysis-buffer (50鈥塵M Tris pH 7.5, 150鈥塵M NaCl, 10% glycerol, 0.5% Triton X-100, 2鈥塵M EDTA, 25鈥塵M glycerophosphate, 100鈥塵M NaF, 200鈥塵M Na3VO4, 1鈥塵g/ml leupeptin, 1鈥塵g/ml aprotinin, and 1鈥塵M PMSF). According to the manufacturer鈥檚 protocol, the insoluble material in cell lysates was removed via centrifugation, and the recovered supernatant was immunoprecipitated with Protein G-coated magnetic Dynabeads (Invitrogen) and 10鈥壜礸 of each of the following antibodies separately: anti-JMJD3 (ab85392, Abcam); anti-C/EBP尾 (sc-150脳, Santa Cruz); anti-FLAG (F7425, Sigma), and control IgG (ab172730, Abcam). To be prepared for western blotting analysis, firstly the immunoprecipitates were washed four times with 1鈥塵l lysis-buffer, then resuspended in 50鈥壜祃 2脳 Laemmli sample buffer (125鈥塵M Tris pH 6.8, 4% SDS, 25% glycerol, 0.1% bromophenol blue, 5% 尾-mercaptoethanol), and finally boiled at 95鈥壜癈 for 10鈥塵in. Control (INPUT) was made by 50鈥壜祃 cell lysates processed for all steps except for the incubation with Protein G-coated magnetic Dynabeads and antibodies. The uncropped scans of blots are shown in the Supplementary Fig.聽7.Flow cytometry analysis and cell sortingAll antibodies were purchased from BD PharMingen or eBiosciences (CA, USA) as follows: PE-conjugated CD11b, APC-conjugated Annexin V, and APC-conjugated Ki67. Total cells were Fc-blocked and stained with indicated combinations of antibodies for 30鈥塵in on ice, then washed three times and resuspended in 1% FBS/PBS. For apoptosis analysis, cells were resuspended with binding buffer and stained with Annexin V and 7-AAD for 15鈥塵in at 25鈥壜癈 in the dark. For cell cycle analysis, cells were thoroughly suspended and incubated with fixation and permeabilization solution for 20鈥塵in at room temperature, washed twice with BD Perm/Wash buffer, and stained with KI-67 and HO33342 for 30鈥塵in. The flow cytometric data were collected on a BD Calibur or a LSRII flow cytometer and analyzed using FlowJo software or Summit software. For the fluorescence-activated cell sorting (FACS), the nucleated cells were stained with the indicated antibodies and resuspended in 2% FBS/PBS. The cells were sorted using a MoFlo machine (Beckman Coulter).Establishment of JMJD3 knockout cell lineFor establishing JMJD3 knockout HL-60 cell lines, the gRNAs were designed and cloned in a U6 targeting vector61, and the single clones were established by dilution cloning. The knockout efficiencies were confirmed by western blotting assay. Guide RNA sequence used was: JMJD3 exon1 5鈥?GGCAGCCATGCGCTACGAGG-3鈥?Lentivirus transduction and siRNA transfectionAll the plasmid for packaging lentivirus, including pMD2.G and psPAX2, were purchased from Addgene (Cambridge, MA). Firstly, 5鈥壩糶 pMD2.G, 10鈥壩糶 psPAX2, and 6鈥壩糶 empty vector plasmids (pLVX-IRES-GFP or pLVX-IRES-YFP) or 12鈥壩糶 JMJD3 constructs (pLVX-IRES-GFP-JMJD3-WT or pLVX-IRES-YFP-JMJD3-WT) or catalytically inactive JMJD3 mutant (pLVX-IRES-GFP-JMJD3-H1390A) were co-transfected into HEK-293T cells in 100鈥塵m cell culture dish with Sofast Effectene Transfection Reagent (Sunmabio, China). The lentiviral particles were harvested at 48 and 72鈥塰 after transfection and concentrated with XE-90 Super Speed Centrifuger (BECKMAN). The lentiviruses were subsequently used to infect leukemic cell lines or primary AML blast samples62. Leukemia cells or primary AML blasts were counted and spin-infected with lentiviral particles. Finally, leukemia cells were washed with PBS 12鈥塰 after infection. GFP+ cells were isolated by FACS after 3 days and sorted again after 5 days; primary AML blasts were washed with PBS 12鈥塰 after infection. GFP+ cells were isolated by FACS after 2 days. For C/EBP尾 overexpression, HL-60 cells were spin-infected with lentivirus containing empty control vector (pLVX-IRES-tdTomato) or C/EBP尾 (pLVX-IRES-tdTomato-C/EBP尾), tdTomato+ cells were isolated by FACS after 3 days and sorted again after 1 week.C/EBP尾, RIPK3, and JUNB siRNAs (Genomeditech, China) were transfected into HL-60 cells at a concentration of 50鈥塶M using an electroporation system (GP7901, Genloci, China) according to the manufacturer鈥檚 instructions. The following siRNA sequences were used in this study: C/EBP尾-siRNA-1, sense, 5鈥?GCCCUGAGUAAUCACUUAAAGTT-3鈥? C/EBP尾-siRNA-1, antisense, 5鈥?CUUUAAGUGAUUACUCAGGGCTT-3鈥? C/EBP尾-siRNA-2, sense, 5鈥?GUAUAUUUUGGGAAUCUUUTT-3鈥? C/EBP尾-siRNA-2, antisense, 5鈥?AAAGAUUCCCAAAAUAUACTT-3鈥? C/EBP尾-siRNA-3, sense, 5鈥?GGCCCUGAGUAAUCGCUUATT-3鈥? C/EBP尾-siRNA-3, antisense, 5鈥?UAAGCGAUUACUCAGGGCCTT-3鈥? RIPK3-siRNA-1, sense, 5鈥?CCAGCACUCUCGUAAUGAUTT-3鈥? RIPK3-siRNA-1, antisense, 5鈥?AUCAUUACGAGAGUGCUGGTT-3鈥? RIPK3-siRNA-2, sense, 5鈥?CCGGCUUAGAAGGACUGAATT-3鈥? RIPK3-siRNA-2, antisense, 5鈥?UUCAGUCCUUCUAAGCCGGTT-3鈥? RIPK3-siRNA-3, sense, 5鈥?GAACUGUUUGUUAACGUAATT-3鈥? RIPK3-siRNA-3, antisense, 5鈥?UAUAUGUUAACGAGCGGUCTT-3鈥? JUNB-siRNA-1, sense, 5鈥?CUCUCUACACGACUACAAATT-3鈥? JUNB-siRNA-1, antisense, 5鈥?UUUGUAGUCGUGUAGAGAGTT-3鈥? JUNB-siRNA-2, sense, 5鈥?CGCCGACGGCUUUGUCAAATT-3鈥? JUNB-siRNA-2, antisense, 5鈥?UUUGACAAAGCCGUCGGCGTT-3鈥? JUNB-siRNA-3, sense, 5鈥?AGACCAAGAGCGCAUCAAATT-3鈥? JUNB-siRNA-3, antisense, 5鈥?UUUGAUGCGCUCUUGGUCUTT-3鈥? JMJD3-siRNA-1, sense, 5鈥?CGCUGACCAUUACCAAACUTT-3鈥? JMJD3-siRNA-1, antisense, 5鈥?AGUUUGGUAAUGGUCAGCGTT-3鈥? JMJD3-siRNA-2, sense, 5鈥?GUGACAAGGAGACCUUUAUTT-3鈥? JMJD3-siRNA-2, antisense, 5鈥?AUAAAGGUCUCCUUGUCACTT-3鈥? JMJD3-siRNA-3, sense, 5鈥?GAGACCUCGUGUGGAUUAATT-3鈥? JMJD3-siRNA-3, antisense, 5鈥?UUAAUCCACACGAGGUCUCTT-3鈥? JMJD3-siRNA-4, sense, 5鈥?GCGAUGUGGAGGUGUUUAATT-3鈥? JMJD3-siRNA-4, antisense, 5鈥?UUAAACACCUCCACAUCGCTT-3鈥?Human AML repopulation assayHL-60 cells were transplanted into NOD-SCID mice by intravenously injection63. Briefly, HL-60 cells were transduced with control, JMJD3-, or H1390A mutant-expressing lentiviral vector and sorted out by FACS. Ten-week-old female NOD-SCID mice were sublethally irradiated with 300鈥塩Gy and then intravenously injected with 5鈥壝椻€?06 transduced HL-60 cells resuspended in 200鈥壜祃 PBS containing 1% FBS. About 35 days after transplantation, the PB, BM, spleen, and liver were assessed for the leukemic repopulation.Leukemia cell transplantationGFP+ BM leukemic blasts expressing the hPML-RAR伪-, hAML1-ETO9a-, or hMLL-AF9 were first infected with pLVX-IRES-YFP or pLVX-IRES-YFP-JMJD3-WT lentiviral vector during a short-term in vitro culture, then the GFP+YFP+ leukemic cells were transplanted into syngeneic mice to allow them to repopulate in vivo. For leukemic cells derived from hPML-RAR伪-transgenic mice, 6鈥?-week-old female FVB/NJ mice were sublethally irradiated with 400鈥塩Gy and then intravenously injected with 1鈥壝椻€?06 transduced leukemic cells resuspended in 200鈥壩糽 PBS. For leukemic cells expressing hAML1-ETO9a or hMLL-AF9, 6鈥?-week-old female C57BL/6J mice were sublethally irradiated with 400鈥塩Gy and then intravenously injected with 1鈥壝椻€?06 transduced leukemic cells resuspended in 200鈥壜祃 PBS. In vitro colony-formation assaysPrimary AML blasts samples transduced with control or JMJD3-overexpressed vector were diluted and seeded at 50,000 per 35-mm dishes in methylcellulose medium (MethoCult鈩?H4435, Stem Cell Technologies). HL-60 cells transduced with control or JMJD3-overexpressed vector were further transfected with NC or C/EBP尾 siRNA, these cells were diluted and seeded at 5000 per 35-mm dishes in methylcellulose medium (MethoCult鈩?M3434, Stem Cell Technologies). The number of colonies with more than 50 cells was counted after 2 weeks.Bioinformatics analyses with GEO and TCGA dataThe microarray expression data in BM and PB mononuclear cells of AML patients (including seven BM or 19 PB samples) and in normal counterparts (ten BM and ten PB samples) were obtained from the GEO GSE9476 dataset64. Data were first normalized using Robust Multi-array Average (RMA) across samples65. The unpaired Student鈥檚 t test per gene probe was used to determine the significant difference between sample categories. The mRNA expression data and clinical information of AML samples were obtained from a patient cohort reported by Verhaak and colleagues22. For AML patients, we correlated the expression levels with the outcome of patients, and observed that boundaries defined as 0鈥?5% (low) and 55鈥?00% (high) of JMJD3 expression predicted outcome of patients. For AML patients with M0, M1, M2, and M3 subtypes, or AML patients with M4 and M5 subtypes, boundaries defined as 0鈥?0% (low) and 50鈥?00% (high) of JMJD3 expression predicted outcome of patients. Survival analysis was performed using Kaplan鈥揗eier analysis and the log-rank test was used to assess the statistical significance. The mRNA expression data of 179 AML samples were obtained from TCGA AML database66, for correlation analysis, scatter plots with regression curves (blue), and 95% prediction intervals (red) indicate the positive correlations among JMJD3, C/EBP尾, or RIPK3. Correlation coefficient r and p values are shown.Gene-set enrichment analysis and gene ontology analysisGSEA was performed using the Broad Institute web platform by pre-ranking the RNA-seq list based on log2-fold change. Gene ontology analysis was performed with DAVID tools (http://david.abcc.ncifcrf.gov/tools.jsp).H3K4me3/H3K27me3 gain and loss analysesHistone modification status changes between the JMJD3 knockout and parental HL-60 cells were determined across the genome using the following method. Briefly described, the total numbers of reads of H3K4me3/H327me3 around gene TSSs (卤3鈥塳b) were calculated. For each gene, the fold change between the two samples was calculated (JMJD3 knockout versus parental) and greater than 1.5 is defined as significant epigenetic change.ChIP-seq data analysisAML1-ETO ChIP-seq data for Kasumi-1 cells were obtained from ref. 26 (GEO accession: GSE65427), PML and RAR伪 ChIP-seq data for NB4 and UPR9 cells were obtained from ref. 27 (GEO accession: GSE18886). MLL-AF9 ChIP-seq data for leukemic blast cells were obtained from the published work by Bernt et al. (GEO accession: GSE29130)28. ChIP-seq data were processed by Cistrome analysis pipeline and were loaded in UCSC genome browsers for visualization67.Statistical analysisMicrosoft Excel and GraphPad Prism softwares were used for statistical analysis. Two-tailed Student鈥檚 t test was used for statistical analysis unless otherwise indicated. The Kaplan鈥揗eier method was used to plot survival curves and the log rank test was used to evaluate statistical differences. The hypergeometric test was performed in R to calculate the statistical significance of overlapped genes illustrated by Venn diagrams. A p value of less than 0.05 was considered statistically significant. Data are presented as mean鈥壜扁€塖EM.Data availabilityThe accession number for the raw data of RNA-seq and ChIP-seq reported in this paper is GEO: GSE101891. All other relevant data are available from the corresponding author on request. References1.Alvarez-Errico, D., Vento-Tormo, R., Sieweke, M. Ballestar, E. Epigenetic control of myeloid cell differentiation, identity and function. Nat. Rev. Immunol. 15, 7鈥?7 (2015).Article聽 PubMed聽 CAS聽Google Scholar聽 2.Swigut, T. Wysocka, J. H3K27 demethylases, at long last. Cell 131, 29鈥?2 (2007).Article聽 PubMed聽 CAS聽Google Scholar聽 3.Salminen, A., Kaarniranta, K., Hiltunen, M. Kauppinen, A. Histone demethylase Jumonji D3 (JMJD3/KDM6B) at the nexus of epigenetic regulation of inflammation and the aging process. J. Mol. Med. 92, 1035鈥?043 (2014).Article聽 PubMed聽 CAS聽Google Scholar聽 4.Miller, S. A., Mohn, S. E. Weinmann, A. S. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression. Mol. Cell 40, 594鈥?05 (2010).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 5.Shi, X. et al. An epigenetic switch induced by Shh signalling regulates gene activation during development and medulloblastoma growth. Nat. Commun. 5, 5425 (2014).Article聽 PubMed聽 PubMed Central聽Google Scholar聽 6.Chen, S. et al. The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes Dev. 26, 1364鈥?375 (2012).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 7.Lan, F. et al. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature 449, 689鈥?94 (2007).ADS聽 Article聽 PubMed聽 CAS聽Google Scholar聽 8.Merkwirth, C. et al. Two conserved histone demethylases regulate mitochondrial stress-induced longevity. Cell 165, 1209鈥?223 (2016).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 9.De Santa, F. et al. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130, 1083鈥?094 (2007).Article聽 PubMed聽 CAS聽Google Scholar聽 10.De Santa, F. et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 28, 3341鈥?352 (2009).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 11.Yan, Q. et al. Jmjd3-mediated epigenetic regulation of inflammatory cytokine gene expression in serum amyloid A-stimulated macrophages. Cell. Signal. 26, 1783鈥?791 (2014).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 12.Achuthan, A. et al. Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J. Clin. Invest. 126, 3453鈥?466 (2016).Article聽 PubMed聽 PubMed Central聽Google Scholar聽 13.Satoh, T. et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 11, 936鈥?44 (2010).Article聽 PubMed聽 CAS聽Google Scholar聽 14.Holla, S. et al. MUSASHI-mediated expression of JMJD3, a H3K27me3 demethylase, is involved in foamy macrophage generation during mycobacterial infection. PLoS Pathog. 12, e1005814 (2016).ADS聽 Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 15.Wei, Y. et al. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+cells. Leukemia 27, 2177鈥?186 (2013).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 16.Li, Q. et al. Critical role of histone demethylase Jmjd3 in the regulation of CD4+T-cell differentiation. Nat. Commun. 5, 5780 (2014).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 17.Manna, S. et al. Histone H3 lysine 27 demethylases Jmjd3 and Utx are required for T-cell differentiation. Nat. Commun. 6, 8152 (2015).Article聽 PubMed聽 PubMed Central聽Google Scholar聽 18.Anderton, J. A. et al. The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin鈥檚 Lymphoma. Oncogene 30, 2037鈥?043 (2011).Article聽 PubMed聽 CAS聽Google Scholar聽 19.Mathur, R. et al. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica 102, 373鈥?80 (2017).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 20.Zhang, Y. et al. JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms. Oncotarget 7, 29387鈥?9399 (2016).PubMed聽 PubMed Central聽Google Scholar聽 21.Ntziachristos, P. et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513鈥?17 (2014).ADS聽 Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 22.Verhaak, R. G. et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94, 131鈥?34 (2009).Article聽 PubMed聽Google Scholar聽 23.Brown, D. et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 2551鈥?556 (1997).ADS聽 Article聽 PubMed聽 CAS聽Google Scholar聽 24.Yan, M. et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat. Med. 12, 945鈥?49 (2006).Article聽 PubMed聽 CAS聽Google Scholar聽 25.Long, J. et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia 31, 2761鈥?770 (2017).Article聽 PubMed聽 CAS聽Google Scholar聽 26.Li, Y. et al. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia. Blood 127, 233鈥?42 (2016).Article聽 PubMed聽 CAS聽Google Scholar聽 27.Martens, J. H. et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 17, 173鈥?85 (2010).Article聽 PubMed聽 CAS聽Google Scholar聽 28.Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66鈥?8 (2011).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 29.Agger, K. et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 23, 1171鈥?176 (2009).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 30.Barradas, M. et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 23, 1177鈥?182 (2009).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 31.Zhang, H. et al. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 116, 2462鈥?471 (2010).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 32.Akagi, T. et al. Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBPbeta-deficient hematopoietic cells. Blood 111, 2999鈥?004 (2008).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 33.Saleh, D. Degterev, A. Emerging roles for RIPK1 and RIPK3 in pathogen-induced cell death and host immunity. Curr. Top. Microbiol. Immunol. 403, 37鈥?5 (2017).PubMed聽 CAS聽Google Scholar聽 34.Hockendorf, U. et al. RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell 30, 75鈥?1 (2016).Article聽 PubMed聽 CAS聽Google Scholar聽 35.Passegue, E., Wagner, E. F. Weissman, I. L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119, 431鈥?43 (2004).Article聽 PubMed聽 CAS聽Google Scholar聽 36.Somervaille, T. C. Cleary, M. L. PU.1 and Junb: suppressing the formation of acute myeloid leukemia stem cells. Cancer Cell 10, 456鈥?57 (2006).Article聽 PubMed聽 CAS聽Google Scholar聽 37.Schenk, T. et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18, 605鈥?11 (2012).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 38.Wang, Z. Y. Chen, Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111, 2505鈥?515 (2008).Article聽 PubMed聽 CAS聽Google Scholar聽 39.Duprez, E., Wagner, K., Koch, H. Tenen, D. G. C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J. 22, 5806鈥?816 (2003).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 40.Girardi, T., Vicente, C., Cools, J. De Keersmaecker, K. The genetics and molecular biology of T-ALL. Blood 129, 1113鈥?123 (2017).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 41.Martinelli, P. et al. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood 117, 6617鈥?626 (2011).Article聽 PubMed聽Google Scholar聽 42.Williams, K. et al. The histone lysine demethylase JMJD3/KDM6B is recruited to p53 bound promoters and enhancer elements in a p53 dependent manner. PLoS ONE 9, e96545 (2014).ADS聽 Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 43.Akdemir, K. C. et al. Genome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells. Nucleic Acids Res. 42, 205鈥?23 (2014).Article聽 PubMed聽 CAS聽Google Scholar聽 44.McLaughlin-Drubin, M. E., Park, D. Munger, K. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc. Natl Acad. Sci. USA 110, 16175鈥?6180 (2013).ADS聽 Article聽 PubMed聽Google Scholar聽 45.Kumagai, T. et al. Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int. J. Cancer 124, 827鈥?33 (2009).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 46.Yamamoto, K. et al. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPalpha. Carcinogenesis 35, 2404鈥?414 (2014).Article聽 PubMed聽 CAS聽Google Scholar聽 47.Pan, M. et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat. Cell Biol. 18, 1090鈥?101 (2016).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 48.Jakobs, A. et al. An isoform-specific C/EBPbeta inhibitor targets acute myeloid leukemia cells. Leukemia 30, 1612鈥?615 (2016).Article聽 PubMed聽 CAS聽Google Scholar聽 49.Watanabe-Okochi, N. et al. The shortest isoform of C/EBPbeta, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model. Blood 121, 4142鈥?155 (2013).Article聽 PubMed聽 CAS聽Google Scholar聽 50.Yan, Y. et al. Transcription factor C/EBP-beta induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells. Cell Death Differ. 23, 1232鈥?242 (2016).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 51.Dai, J. P., Lu, J. Y., Zhang, Y. Shen, Y. F. Jmjd3 activates Mash1 gene in RA-induced neuronal differentiation of P19 cells. J. Cell. Biochem. 110, 1457鈥?463 (2010).Article聽 PubMed聽 CAS聽Google Scholar聽 52.Mueller, B. U. et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 107, 3330鈥?338 (2006).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 53.Guerzoni, C. et al. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 107, 4080鈥?089 (2006).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 54.Hayashi, Y. et al. C/EBPbeta promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion. Leukemia 27, 619鈥?28 (2013).Article聽 PubMed聽 CAS聽Google Scholar聽 55.Hall, C. J. et al. Infection-responsive expansion of the hematopoietic stem and progenitor cell compartment in zebrafish is dependent upon inducible nitric oxide. Cell Stem Cell 10, 198鈥?09 (2012).Article聽 PubMed聽 CAS聽Google Scholar聽 56.Ignatz-Hoover, J. J. et al. The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia 29, 918鈥?26 (2015).Article聽 PubMed聽 CAS聽Google Scholar聽 57.Sharma, A. et al. Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia 29, 157鈥?68 (2015).Article聽 PubMed聽 CAS聽Google Scholar聽 58.Herault, A. et al. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature 544, 53鈥?8 (2017).ADS聽 Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 59.Li, H. Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754鈥?760 (2009).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 60.Thorvaldsdottir, H., Robinson, J. T. Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178鈥?92 (2013).Article聽 PubMed聽 CAS聽Google Scholar聽 61.Maeder, M. L. et al. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10, 977鈥?79 (2013).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 62.Fu, C. T. et al. An evolutionarily conserved PTEN-C/EBPalpha-CTNNA1 axis controls myeloid development and transformation. Blood 115, 4715鈥?724 (2010).Article聽 PubMed聽 CAS聽Google Scholar聽 63.Saland, E. et al. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer J. 5, e297 (2015).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 64.Stirewalt, D. L. et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 47, 8鈥?0 (2008).Article聽 PubMed聽 CAS聽Google Scholar聽 65.Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).Article聽 PubMed聽 PubMed Central聽 CAS聽Google Scholar聽 66.Ley, T. J. et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Eng. J. Med. 368, 2059鈥?074 (2013).Article聽 CAS聽Google Scholar聽 67.Mei, S. et al. Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res. 45, D658鈥揇662 (2017).Article聽 PubMed聽 CAS聽Google Scholar聽 Download referencesAcknowledgementsThis work was supported by grants from the Chinese National Key Basic Research Project (2013CB966803), the National Scientific Foundation of China (81430002 and 81770206), and Samuel Waxman Cancer Research Foundation.Author informationAuthor notesThese authors contributed equally: Shan-He Yu, Kang-Yong Zhu, Juan Chen.AffiliationsState Key Laboratory for Medical Genomics, Shanghai Institute of Hematology and Collaborative Innovation Center of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao-Tong University School of Medicine, Shanghai, 200025, ChinaShan-He Yu,聽Kang-Yong Zhu,聽Juan Chen,聽Xiang-Zhen Liu,聽Peng-Fei Xu,聽Wu Zhang,聽Li Yan,聽He-Zhou Guo聽 聽Jiang ZhuSchool of Life Sciences Biotechnology, Shanghai Jiao-Tong University, Shanghai, 200040, ChinaHe-Zhou Guo聽 聽Jiang ZhuAuthorsShan-He YuView author publicationsYou can also search for this author in PubMed聽Google ScholarKang-Yong ZhuView author publicationsYou can also search for this author in PubMed聽Google ScholarJuan ChenView author publicationsYou can also search for this author in PubMed聽Google ScholarXiang-Zhen LiuView author publicationsYou can also search for this author in PubMed聽Google ScholarPeng-Fei XuView author publicationsYou can also search for this author in PubMed聽Google ScholarWu ZhangView author publicationsYou can also search for this author in PubMed聽Google ScholarLi YanView author publicationsYou can also search for this author in PubMed聽Google ScholarHe-Zhou GuoView author publicationsYou can also search for this author in PubMed聽Google ScholarJiang ZhuView author publicationsYou can also search for this author in PubMed聽Google ScholarContributionsS.H.Y. performed most of the experiments, analyzed the data, and contributed to writing the manuscript. K.Y.Z. performed the lentivirus transduction and coimmunoprecipitation experiments. J.C., X.Z.L., W.Z., L.Y., and H.-Z.G. performed the flow cytometry experiments. P.F.X. contributed ideas and advice. J.Z. supervised the project and wrote the manuscript.Corresponding authorCorrespondence to Jiang Zhu.Ethics declarations Competing interests The authors declare no competing interests. Additional informationPublisher\'s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Electronic supplementary material Mei Qin, Fei Han, Jian Wu, Feng-xia Gao, Yuan Li, De-xin Yan, Xue-mei He, Yang Long, Xiao-ping Tang, De-lian Ren, Yan Gao Tian-yang Dai BMC Cancer (2021) Zhi Cao, Xiaolei Shi, Feng Tian, Yu Fang, Jason Boyang Wu, Stefan Mrdenovic, Xinwen Nian, Jin Ji, Huan Xu, Chen Kong, Yalong Xu, Xi Chen, Yuhua Huang, Xuedong Wei, Yongwei Yu, Bo Yang, Leland W. K. Chung Fubo Wang Cell Death Disease (2021) Jiahong Tan, Xu Zheng, Mengchen Li, Fei Ye, Chunyan Song, Cheng Xu, Xiaoxue Zhang, Wenqian Li, Ya Wang, Shaoqing Zeng, Huayi Li, Gang Chen, Xiaoyuan Huang, Ding Ma, Dan Liu Qinglei Gao Oncogene (2021) Lixin Zheng, Shengru Wu, Jing Shen, Xiaoying Han, Chunjia Jin, Xiaodong Chen, Shengguo Zhao, Yangchun Cao Junhu Yao Journal of Animal Science and Biotechnology (2020) Cates Mallaney, Elizabeth L. Ostrander, Hamza Celik, Ashley C. Kramer, Andrew Martens, Alok Kothari, Won Kyun Koh, Emily Haussler, Naoki Iwamori, Paul Gontarz, Bo Zhang Grant A. Challen Leukemia (2019) CommentsBy submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Sign up for the Nature Briefing newsletter 鈥?what matters in science, free to your inbox daily.